r β-Adrenergic stimulation enhances Ca 2+ entry via L-type Ca V 1.2 channels, causing stronger contraction of cardiac muscle cells.
Introduction
The sympathetic system regulates cardiac function, largely through the β-adrenergic receptors (β-ARs), causing multiple changes in Ca 2+ handling and consequently in force, rate and duration of cardiac contraction (Bers, 2008) . Increased β-adrenergic stimulation is harmful in chronic heart failure, and β-AR-blocking drugs are used to treat a wide range of cardiovascular disorders (Florea & Cohn, 2014) . In the classical signalling scheme, adrenaline (epinephrine) or noradrenaline (norepinephrine) binding to β-AR activates the G protein Gα s , stimulating adenylyl cyclase, which increases intracellular levels of cyclic AMP (cAMP). cAMP activates protein kinase A (cAMP-dependent protein kinase, PKA) by dissociating the regulatory subunits (PKA-RS) from the catalytic subunits (PKA-CS). PKA-CS phosphorylates key proteins involved in myocyte contraction, such as the L-type voltage gated Ca 2+ channel Ca V 1.2 in the cardiac sarcolemmal T-tubules, major Ca 2+ -handling proteins of the sarcoplasmic reticulum, certain proteins of the myofilaments, etc. (Wehrens et al. 2005; Bers, 2008; Vinogradova & Lakatta, 2009 ).
The Ca V 1.2 channel mediates the fundamental mechanism that initiates the cardiac cell contraction: depolarization-induced Ca 2+ entry via Ca V 1.2 triggers the Ca 2+ -induced Ca 2+ release from the sarcoplasmic reticulum, which underlies the excitation-contraction coupling (Bers, 2000) . β-Adrenergic stimulation, through the activation of PKA, increases Ca 2+ entry via Ca V 1.2 by enhancing the channel's gating by voltage and increasing its open probability (Osterrieder et al. 1982; Reuter et al. 1982; Trautwein et al. 1982; Cachelin et al. 1983; Yue et al. 1990 ). The increased Ca 2+ influx leads to strengthening of cardiac contraction. This β-adrenergic action is an important mechanism for regulation of heartbeat by positive inotropic, positive chronotropic and positive lusitropic effects, taking place under a variety of physiological conditions. Nevertheless, despite extensive research, the mechanism linking β-AR and PKA activation to Ca V 1.2 enhancement has not been fully elucidated (reviewed in: Weiss et al. 2013; Hofmann et al. 2014; Catterall, 2015; Morrow & Marx, 2015) .
Ca V 1.2 in the heart comprises three subunits: the pore-forming α 1C , the extracellular α 2 /δ, and the cytosolic Ca V β subunit (Catterall, 2000; Dolphin, 2012; Campiglio & Flucher, 2015) . Both α 1C and Ca V β are phosphorylated by PKA in vitro and in vivo, and the leading concept is that PKA regulation is mediated by phosphorylation of specific sites in the channel, mainly in the C-terminus (CT) of α 1C (reviewed by Catterall, 2015) .
The majority of α 1C molecules in cardiomyocytes are proteolytically cleaved around amino acid (a.a.) 1800 (Hulme et al. 2005 (Hulme et al. , 2006 ; the exact cleavage site is uncertain (Yang et al. 2013) . The clipped distal CT (dCT) remains attached non-covalently to the truncated α 1C , and reduces current density and voltage sensitivity Klockner et al. 1997; Gerhardstein et al. 2000; Gao et al. 2001; Crump et al. 2013) . The dCT and its cleavage have been postulated to play an important role in β-AR modulation of Ca V 1.2 in cardiomyocytes (Ganesan et al. 2006; Fuller et al. 2010; Domes et al. 2011; Fu et al. 2011 Fu et al. , 2013 Fu et al. , 2014 .
Several mechanisms which assigned crucial roles to various PKA phosphorylation sites in α 1C and Ca V β subunits, based on biochemical and heterologous expression data, have been proposed but remained controversial. Inconsistencies between studies prevail, even with the same mammalian cell line such as HEK (reviewed in Weiss et al. 2013) , presumably due to variability of research methodologies or model systems. The importance of the cardiac cellular environment is not fully understood. Recent studies with animal models carrying targeted mutations and in transfected cardiac cells have challenged most of the proposed mechanisms (Ganesan et al. 2006; Lemke et al. 2008; Brandmayr et al. 2012; Jones et al. 2012; Yang et al. 2013 ).
An important proposed mechanism emerged from the reconstitution of Ca V 1.2 upregulation by PKA in the tsA-201 mammalian cell line (Fuller et al. 2010) . Essential requirements for reconstituting the PKA regulation were the truncation of the dCT of α 1C , the presence of the clipped part of the CT (amino acids (a.a.) 1800-2171) as a separate protein, and the presence of the cardiac A-kinase-anchoring protein AKAP15 (also termed AKAP18α; Fraser et al. 1998) . Mutagenesis suggested that serine 1700 (S1700) and threonine 1704 (T1704) were necessary for the PKA effect in tsA-201 cells, and the proposed model attributed the Ca V 1.2 enhancement to a relief of dCT's inhibitory effect upon PKA phosphorylation of S1700 (Fuller et al. 2010) . Follow-up studies in a mouse model showed that replacement of serine 1700 or of threonine 1704 by an alanine residue reduced both 'basal' Ca 2+ currents and sensitivity to β-AR agonists (Fu et al. 2013 (Fu et al. , 2014 . Nevertheless, the two mutations did not fully eliminate the β-adrenergic regulation (Fu et al. 2013) . A prominent β-adrenergic stimulation of Ca V 1.2, similar to that seen in wild-type cardiomyocytes, also persisted in a knock-in genetically engineered mouse model with the alanine mutations S1700A and T1704A (Yang et al. 2013) . The exclusive requirement for AKAP15, or another PKA-anchoring protein, AKAP79, could not be confirmed either, since β-adrenergic regulation endured in AKAP knock-out mice (Nichols et al. 2010; Jones et al. 2012) . These complex, controversial results may indicate redundancy, i.e. the existence of multiple pathways, of PKA control of Ca V 1.2 gating in native cardiomyocytes (Weiss et al. 2013) . According to this view, some of the pathways suggested by heterologous studies may, in fact, mediate part of the PKA action (such as the phosphorylation of S1700), but their lack in genetically engineered animal models may be compensated by other pathways. Therefore, we posit that, whereas validation in genetically engineered animal models remains essential, further heterologous studies are needed to identify the putative novel or undetected components of the intricate mechanism of PKA regulation of Ca V 1.2.
We sought to utilize the experimental approach developed in tsA-201 cells (Fuller et al. 2010 ) to reconstitute and better understand the PKA regulation of Ca V 1.2 in Xenopus oocytes. Oocytes, like other heterologous systems, lack the specific cellular architecture of cardiac cells which is undoubtedly important for reconstitution of the complete β-AR cascade. However, they have been successfully used for identification of phosphorylation end-points and additional necessary structural elements in PKA regulation of ion channels such as voltage-gated Na + channels and the cystic fibrosis transmembrane conductance regulator (CFTR) (e.g. Frohnwieser et al. 1997; Wilkinson et al. 1997; Csanady et al. 2005) .
We found that, like in tsA-201, cleavage of dCT was necessary for upregulation of the PKA-dependent Ca V 1.2 current. However, PKA-induced enhancement of Ca V 1.2 currents did not require the presence of either dCT as a separate protein, AKAP15, Ca V β, or the phosphorylation sites S1700 and T1704. The gating element located in the beginning of the N-terminus (NT) of the cardiac isoform of α 1C was necessary for cAMP-dependent upregulation of Ca V 1.2 currents in Xenopus oocytes. These findings suggest that both cytosolic N-and C-termini of α 1C participate in the PKA regulation of the channel, pointing to a new direction in the search for pathway(s) of PKA regulation of cardiac Ca V 1.2.
Methods

Ethical approval
Experiments were approved by Tel Aviv University Institutional Animal Care and Use Committee (permits M-08-081 and M-13-002). Adult female Xenopus laevis frogs were purchased from Xenopus-1 (Dexter, MI, USA), transported to Israel and maintained according to the Guidance on the housing and care of the African clawed frog Xenopus laevis (Research Animals Department, RSPCA, UK). The frogs were housed in Tel Aviv University Medical School Animal Facility and handled essentially as described (Kahanovitch et al. 2014) . Female frogs were maintained at 20 ± 2°C on a 10 h light/14 h dark cycle. Frogs were anaesthetized in a 0.17% solution of procainemethanesulphonate (MS222), and portions of ovary were removed through an incision on the abdomen. The incision was sutured and the animal was held in a separate tank until it had fully recovered from the anaesthesia. Afterwards it was returned to a separate tank for post-operational animals. The animals did not show any signs of post-operational distress and were allowed to recover for at least 3 months until the next surgery. Following the final collection of oocytes, anaesthetized frogs were killed by decapitation and double pithing.
DNA constructs and RNA
The DNA constructs used were: the cardiac long-N-terminus (LNT) isoform of α 1C from rabbit (Mikami et al. 1989; GenBank: X15539) and the corresponding mouse α 1C isoform (NP 001242928; Link et al. 2009 ), Ca V β 2b (GenBank: X64297.1; Ca V β2N4 according to the comprehensive nomenclature, Hofmann et al. 2014) , α 2 δ1 (GenBank: M21948), AKAP15 (GenBank: AF047716) and enhanced green fluorescent protein (EGFP)-fused Ht31 (Carr et al. 1992; Lynch et al. 2005) . The short-NT (SNT) α 1C used here was the NT SL construct (Kanevsky & Dascal, 2006) in which the initial segment of the long-NT (LNT) α 1C (encoding the first 46 a.a.) was replaced with that encoded by exon 1 (16 a.a. long). DNAs of rabbit and mouse α 1C 1821, in which the dCT is truncated, were prepared by the removal of the cDNA segment encoding the dCT from the plasmid and introducing a stop codon after valine 1821, by PCR. NT constructs of rabbit α 1C were constructed by subcloning into a LNT α 1C 1821 template (Shistik et al. 1998; Kanevsky & Dascal, 2006) . Mouse α 1C 5 1821 DNA (deletion of a.a. 2-5 in the mouse α 1C 1821 protein) was constructed by PCR procedures and inserted into the pMXT vector. All mouse α 1C constructs additionally contained the double mutation T1066Y, Q1070M, which renders the channel dihydropyridine insensitive but does J Physiol 595.10 not affect the regulation by PKA (Yang et al. 2013) . The following mutations were made in Ca V β 2b . To construct Ca V β-4A, serines 296, 479/80 and 576 were replaced by alanines. To construct Ca V β 2b -CT trunc , a stop codon was introduced after the nucleotide position corresponding to amino acid 471, together with the point mutation S296A (see also Pankonien et al. 2012) . Mutations were introduced by PCR using the standard site-directed mutagenesis. All constructs were confirmed by DNA sequencing. CFTR (GenBank: M28668) was in a pSP64 vector. All other cDNA constructs used for RNA synthesis were inserted into the pGEM-GSB (Shistik et al. 1998) or pGEM-HJ vectors, which are derivatives of pGEM-HE (Liman et al. 1992 ) and contain 5 and 3 UTR from Xenopus β-globin. The RNAs were prepared using a standard procedure described previously (Dascal & Lotan, 1992) . The amount of injected RNA, per oocyte, for the full-length α 1C was 5 ng. For the α 1C 1821 constructs, the injected RNA amounts were: 0.5-1 ng for LNT, LNT 20-46, LNT 5 and LNT 5 20-46, and 0.3-0.5 ng RNA for LNT 20, LNT 139, SNT, SNT+a.a.2-5 and SNT+a.a.20-46. When Ca V β was not expressed, we injected 7 ng RNA of α 1C 1821 and α 2 δ1.
The following DNA constructs were used for protein purification in Escherichia coli: His-tagged Cα-subunit of PKA (His-PKA-CS, GenBank: NM 008854.5), glutathion-S-transferase (GST)-fused PKA-RIIβ (GST-PKA-RS; GenBank: NM 001030020) and His-tagged human protein kinase inhibitor protein (PKI) (Olsen & Uhler, 1991) (GenBank: S76965.1).
Protein purification and pull-down assays
Proteins were expressed in E. coli (BL21-DE3). For PKA-CS and PKI, respectively, cultures were grown in YT medium at 37°C to an A 600 of 0.6-0.8 and induced with 0.5 or 1 mM isopropyl β-D-thiogalactopyranoside for 6.5 h at 24°C (PKA-CS) or for 3 h at 37°C (PKI), before being collected by centrifugation and stored frozen. Pellets were resuspended in buffer I for PKA-CS (in mM: 50 KH 2 PO 4 , 20 Tris-HCl, 100 NaCl, 5 β-mercaptoethanol, pH 8.0), or buffer II for PKI (in mM: 20 Tris-HCl, 300 NaCl, 0.1% Triton X-100, pH 8.0) with the addition of 15 U ml −1 DNase-I, 10 mg lysozyme, 1 mM phenylmethanesulfonyl fluoride (PMSF) and Protease Inhibitor Cocktail (Roche, Mannheim, Germany). Cells were lysed using a microfluidizer and clarified by centrifugation. Clarified lysate was loaded onto a Ni-NTA column followed by washing (20 mM) and elution (80 mM) with imidazole. Then the protein was subjected to size-exclusion chromatography on Superdex-75 in buffer III-PKA-CS (in mM: 20 KH 2 PO 4 , 20 KCl, 2 DTT, pH 7.5), or buffer IV-PKI (in mM: 20 Tris-HCl, 300 NaCl, 2 DTT, pH 8). PKI was concentrated in a Vivaspin concentrator with 5000 Da cutoff (Sartorius, Göttingen, Germany).
Buffer IV-PKI was used for PKI injection into oocytes (Figs 2 and 3) .
For GST-PKA-RS, the pellet was resuspended in PBS supplemented with 0.1% Triton X-100, 15 U ml
DNase-I, 10 mg of lysozyme, and 1 mM PMSF. The cells were homogenized and lysed with a microfluidizer, and centrifuged for 1 h. The supernatant was loaded onto a glutathione column pre-equilibrated with PBS. Cell extract was loaded on the column and washed with PBS. Protein was eluted with buffer containing (in mM): 50 Tris pH 8.0, 100 NaCl, and 10 glutathione.
Pull-down assays were performed with Ni-NTA resin (Thermo Scientific, Waltham, MA, USA) and washed with buffer containing (in mM): 150 KCl, 50 Tris, 0.6 MgCl 2 , 1 CaCl 2 , 0.5% CHAPS, and 10 imidazole, pH 7.4. Elution was done with 100 mM imidazole. Eluates were run on SDS-PAGE gel and stained with Coomassie Blue.
Electrophysiology
Oocytes were defolliculated by collagenase, injected with RNA and incubated for 2-3 days before recording at 20-22°C in NDE solution (in mM: 96 NaCl, 2 KCl, 1 MgCl 2 , 1 CaCl 2 , 5 Hepes, 2.5 pyruvic acid; plus 50 mg l −1 gentamycin).
Whole-cell Ba 2+ currents (I Ba ) in oocytes were measured using the two-electrode voltage clamp technique (see Fig. 1A ) with a GeneClamp 500 amplifier (Molecular Devices, Sunnyvale, CA, USA). I Ba was recorded in most cases by 20 ms depolarizing pulses from a resting potential of −80 mV to 20 mV, with a 10 s interval between sweeps, in 40 mM Ba 2+ solution (in mM: 40 Ba(OH) 2 , 50 NaOH, 2 KOH, and 5 Hepes, titrated to pH 7.5 with methanesulfonic acid). In some experiments (e.g. Fig. 7 ), for some α 1C -derived chimeras, I Ba amplitudes in 40 mM Ba 2+ solution exceeded 5 μA. In such cases, to avoid artifacts resulting from oocyte series resistance and poor space clamp, recordings were made in 2 mM Ba 2+ solution (in mM: 2 Ba(OH) 2 , 96 NaOH, 2 KOH, and 5 Hepes, titrated to pH 7.5 with methanesulfonic acid). These measurements were used to assess cAMP-induced changes in I Ba amplitude only, and have not been included in amplitude summaries and activation curve fits. In the current-voltage (I-V) protocols, currents were elicited by 20 ms pulses from the holding potential −80 mV to voltages from −50 to +60 mV with 10 mV intervals and 10 s between sweeps. Currents measured in the presence of 200 μM Cd 2+ were subtracted from total I Ba ( Fig. 4D and E) to yield the net I Ba . CFTR currents were measured at −80 mV in ND96 solution (in mM: 96 NaCl, 2 KCl, 1 MgCl 2 , 1 CaCl 2 , 5 Hepes, pH 7.6).
I-V curves were fitted to the Boltzmann equation in the form The comparison among all treatments using one-way ANOVA showed no significant difference between groups injected with cAMP, PKA-CS and forskolin. * * * P < 0.001; * * P = 0.007; ns, not significant.
where G max is the maximal Ba 2+ conductance, V m is the membrane voltage, V rev is the reversal potential of the current, K a is the slope factor and V a is half-maximum activation voltage. The parameters obtained for G max and V rev were then used to calculate fractional conductance at each V m and to construct the conductance-voltage (G-V) curve using the equation.
Injection of cAMP and other substances
In experiments that used pre-injection of the compounds (Figs 2B and 3), oocytes were injected with 50 nl of the substance solution 5-30 min prior to recording. Injection during recording was done with sharp capillary glass micropipettes filled with the desired substances (Fig. 1A) . The compound was pressure-injected into the oocyte as explained in the Results section. The micropipette tip was trimmed so that application of pressure during 1-2 s extruded about 10 nl (1% of oocyte volume). Current stabilized during 1-5 min following insertion of the injection micropipette. Artifacts (sharp shifts in current, e.g. the right panel in Fig. 3D ) following the insertion of the micropipette or injection of the compound were usually minor. Records with insertion or injection artifacts that exceeded 10% of I Ba amplitude were discarded. The final concentrations of injected substances in the oocytes is indicated in the legends. cAMP (Sigma, A6885) was diluted in H 2 O and kept in 1, 20 and 40 mM stock solutions. Injection of 10 nl of cAMP from these stocks gave final concentrations of 10, 200 and 400 μM in the oocyte, respectively. Purified bovine heart PKA-CS (Sigma, P2645) was diluted in Tris-Mg buffer (50 mM Tris-HCl, 10 mM MgCl 2 , pH 7.5) to 16 units μl −1 . Forskolin (Alomone Labs, Jerusalem, Israel) was diluted in DMSO. Rp-cAMPS (Sigma, A165) was diluted in H 2 O.
Giant membrane patches
Giant excised patches of oocyte membrane were prepared as described (Singer-Lahat et al. 2000) . Oocytes were mechanically devitellinized using tweezers in a hypertonic solution (in mM: 6 NaCl, 150 KCl, 4 MgCl 2 , 10 Hepes, pH 7.6) and transferred onto a coverslip in EGTA-containing ND96 solution (in mM: 96 NaCl, 2 KCl, 1 MgCl 2 , 5 Hepes, 5 EGTA, pH 7.6), with their animal pole facing the coverslip, for 30-45 min. The oocytes were then removed with a jet of solution using a Pasteur pipette, leaving a giant membrane patch attached to the coverslip, with the cytosolic part facing the medium, and the extracellular surface facing the coverslip. The coverslip was washed thoroughly with fresh ND96 solution, and fixated using 4% formaldehyde in EGTA-containing ND96 solution for 30 min. Coverslips were mounted on a glass slide. Giant membrane patches were stained with primary antibody for α 1C (1:200; ACC-003, Alomone Labs), followed by incubation with Cy3 fused secondary antibody. The fluorescent labelling was examined by a confocal laser scanning microscope (Zeiss 510 META), using a ×63 oil-immersion objective. Cy3 was excited by a 488 nm laser and the intensities were measured in a 560-569 nm window in the spectral mode. In each experiment, all oocytes from the different groups were studied using a constant set of imaging parameters. Net fluorescence intensity per unit area was obtained by subtracting an averaged background signal measured in the same way on the coverslip outside the oocytes.
Data presentation and statistics
Imaging data on protein expression (Fig. 4A ) have been normalized as described previously (Kanevsky & Dascal, 2006) . Fluorescence intensity in each giant membrane patch was calculated relative to the average signal in the oocytes of the control group of the same experiment. This procedure yields average normalized intensity ± SEM in all treatment groups as well as in the control group.
For experiments that involved the injection of substances during current recording, percentage change was relative to the current before injection (which was taken as 100%), in the same cell. The statistical significance of amplitude changes was analysed using a paired t test on raw data if normally distributed (using the Kolmogorov-Smirnov test), otherwise a Wilcoxon test was performed. Net CFTR current was defined as (I after injection − I before injection ).
Statistical analysis of data obtained from different test samples (e.g. comparison of currents in oocytes pre-injected with different substances) was performed as Oocytes expressing Ca V 1.2 1821 were pre-injected with Tris-NaCl buffer, His-PKI, or not pre-injected. The estimated final concentrations of PKI within the oocyte, assuming a 1 μl cell volume, are shown in μM. Maximal currents in each cell, obtained using an I-V protocol of 10 mV depolarization steps from −60 to 50 mV, were averaged and normalized to control group of the same day. Summary from 2 experiments is shown. Statistical significance was determined using one-way ANOVA followed by Bonferroni t test.
follows. Two-group comparisons were performed using Student's t test. Multiple group comparison was done with one-way ANOVA if the data were normally distributed. ANOVA on ranks was performed whenever the data did not distribute normally. A Bonferroni post hoc test was performed for normally distributed data and Dunn's post hoc test otherwise. Unless specified otherwise, the data in the graphs are presented as mean ± SEM and numbers within or near the bars or symbols indicate number of cells tested (n). Statistical analysis was performed with SigmaPlot 11 (Systat Software Inc., San Jose, CA, USA).
Results
C-terminal truncation of α 1C is necessary for PKA upregulation of Ca V 1.2 in Xenopus oocytes
The majority of previous studies showed that full-length α 1C is not significantly upregulated by cAMP or PKA in Xenopus oocytes (Singer-Lahat et al. 1994; Charnet et al. 1995) , as well as in mammalian CHO, HEK or tsA-201 cell lines Zong et al. 1995; Fuller et al. 2010) . In view of the emerging importance of the C-terminal cleavage of α 1C for PKA regulation (Fuller et al. 2010; Domes et al. 2011; Fu et al. 2011) , we decided to re-evaluate the effect of PKA on Ca V 1.2 in Xenopus oocytes using a dCT-truncated α 1C . We found that this channel is prominently upregulated by PKA (Fig. 1) . We injected cAMP (to activate the endogenous PKA), purified PKA-CS, or other compounds as shown in Fig. 1A , and monitored the ensuing changes in Ca V 1.2 currents. First, we inserted the voltage and the current electrodes and measured the Ba 2+ current (I Ba ) using the two-electrode voltage clamp technique. I Ba was elicited with test pulses to +20 mV every 10 s and continuously monitored during all stages of the experiment. When the current amplitude stabilized, a third micropipette was inserted for pressure injection. The stability of the current amplitude was again verified before the injection of the substances.
We used two distinct α 1C constructs: the full-length rabbit cardiac α 1C (Mikami et al. 1989 ) (2171 a.a., illustration in Fig. 1B) , and the C-terminally truncated α 1C lacking the dCT after valine 1821, α 1C 1821 (1821 a.a., Fig. 1C) . α 1C or α 1C 1821 were expressed, along with the auxiliary subunits Ca V β 2b and α 2 δ1, by injecting corresponding RNAs at a 1:1:1 ratio. The resulting channels are termed here Ca V 1.2 or Ca V 1.2 1821, respectively. Consistent with previous reports Ivanina et al. 2000; Gao et al. 2001; Hulme et al. 2006) , I Ba amplitudes in Ca V 1.2 1821 were higher compared with the full-length Ca V 1.2. In order to maintain similar macroscopic currents, we injected different amounts of the channel RNA: 0.5-1 ng RNA for Ca V 1.2 1821 and 5 ng RNA for Ca V 1.2.
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The modulation of I Ba following the injection of cAMP is illustrated in Fig. 1B for Ca V 1.2 and in Fig. 1C for Ca V 1.2 1821. The left panels in Fig. 1B and C show representative current traces at two time points: t = 1 min, just before cAMP injection, and t = 4 min, 3 min after cAMP injection. The time course of changes in I Ba in the same cells is shown in the right panels in Fig. 1B and C. As expected, the full length Ca V 1.2 I Ba was not modulated by cAMP. In contrast, I Ba of the C-terminally truncated Ca V 1.2 1821 increased following cAMP injection. Figure 1D shows the effect of cAMP on current-voltage (I-V) relations in a representative oocyte, illustrating the increase in whole-cell I Ba (Fig. 1Da ) and the ensuing change in the I-V curve (Fig. 1Db ). An In the set of experiments with Rp-cAMPS, the cAMP-induced increase in Ca V 1.2 1821 I Ba was relatively low (22.5% in the control group, less than the average 35.7% summarized from all experiments in Fig. 1F ), which could reflect low endogenous PKA levels or a high basal phosphorylation of the channel. Statistical significance was determined using one-way ANOVA followed by Bonferroni test, except Da where a t test was applied. * * * P < 0.001.
increase in Ca V 1.2 1821 I Ba was also recorded following the injection of purified PKA-CS protein or the adenylyl cyclase activator, forskolin (Fig. 1E) . We used the cystic fibrosis transmembrane conductance regulator (CFTR) as the positive control for endogenous PKA activation by cAMP, and for PKA-dependent current modulation. CFTR is a chloride channel gated by PKA phosphorylation along with ATP binding (Welsh et al. 1992; Gadsby & Nairn, 1999 ). CFTR's Cl − current (I Cl ) is robustly activated by PKA in Xenopus oocytes (Bear et al. 1991; Uezono et al. 1993) . As expected, both injected cAMP and PKA-CS activated CFTR and elicited large I Cl , usually between 1 and 4 μA (Fig. 1F) . The upregulation in Ca V 1.2 1821 currents is summarized in Fig. 1G Ba amplitudes at +20 mV (a) and plasma membrane expression (b) were measured in oocytes expressing Ca V 1.2 1821 together with increasing levels of dCT. In each experiment both current amplitude and surface labelling intensity were measured and normalized to the group expressing the channel alone. Statistical significance was determined by one-way ANOVA followed by Bonferroni test. * * * P < 0.001; ns, not significant. N = 3 experiments. c, examples of confocal images of giant membrane patches, where the channel levels were quantified with Ca V 1.2 antibody directed to an intracellular loop. B, dose-dependent reduction of I Ba by coexpressed dCT. Oocytes were injected with 1 ng RNA Ca V 1.2 1821 together with increasing amounts of dCT RNA. The leftmost grey point represents channels expressed without dCT. In each experiment, I Ba amplitude was normalized to average I Ba in the control group expressing the channel alone. N = 11 experiments. Statistical significance was determined by one-way ANOVA followed by Bonferroni test. * P < 0.05; * * P < 0.01; * * * P < 0.001. C and D, current-voltage (I-V) relationships in oocytes expressing 1 ng Ca V 1.2 1821 and no dCT or 5 or 12.5 ng dCT RNA, from a representative experiment (n = 5-7 oocytes). Representative records of net I Ba (C) and averaged I-V curves (D). E, averaged conductance-voltage relationships from 3 experiments (n = 25 without dCT, and n = 5-9 with the different doses of dCT RNA). The Boltzmann equation fit parameters are shown in Table 2 . cAMP-evoked CFTR current: summary of two experiments; the difference in effect between the three cAMP doses was not significant (P = 0.611, one-way ANOVA).
increase in I Ba (n = 164; range: 6-100%) was observed following the injection of cAMP to a final concentration of 200 μM in the oocyte. After injections of purified bovine heart PKA-CS (final concentration in the oocyte 0.16 units μl −1 ), I Ba increased by 43 ± 5.5% (n = 20). With recombinant His-tagged PKA-CS (see Fig. 2 ; final concentration 100 nM to 1 μM), the increase was 36 ± 4.7% (n = 17). Figure 1G shows pooled data (40 ± 4.2% increase in I Ba , n = 37; range: 9-114%) for all PKA-CS experiments.
Contrary to cAMP, injection of water or Tris-Mg buffer did not increase I Ba of Ca V 1.2 1821 (Fig. 1E-G) . This indicates that the current enhancement of I Ba seen in Fig. 1C -E is not an injection artifact. The small and statistically non-significant negative change in I Ba reflects the occasional small rundown of I Ba observed following buffer or water injection. This could be happening because of a deterioration of the cell's condition, possibly caused by the insertion of micropipettes.
Our data suggest that the concentrations of cAMP and PKA-CS that we used have produced maximal upregulation of rabbit Ca V 1.2 1821 and of CFTR. All three compounds used (cAMP, PKA-CS or forskolin) produced a similar increase in Ca V 1.2 1821 current (Fig. 1F) . Furthermore, in a separate experiment we verified that a 20-fold dilution of cAMP yielded a similar increase in I Ba : 33.8 ± 5.5% (n = 5) with 10 μM cAMP vs. 33.75 ± 5.1% (n = 4) with 200 μM cAMP in the oocyte. Similarly, 10-400 μM cAMP induced CFTR currents of comparable sizes (Table 1) .
We purified and used recombinant proteins: His-tagged PKA-CS; His-tagged, highly specific heat-stable protein kinase inhibitor protein (PKI) (Walsh et al. 1971; Olsen & Uhler, 1991) ; and GST-tagged PKA-RIIβ regulatory subunit (PKA-RS). To test their functionality, we performed a pull-down assay in which His-tagged PKA-CS, immobilized on nickel agarose beads, bound and pulled down PKA-RS ( Fig. 2A) . In the presence of cAMP, the PKA holoenzyme complex dissociates to a large degree (Beavo et al. 1974; Kim et al. 2007) . In concordance, our pull-down assay showed that in the presence of 40 μM cAMP, PKA-CS did not pull-down PKA-RS. PKI is a PKA-CS pseudo-substrate that competes with the PKA-RS on binding to the active site cleft in PKA-CS and also blocks the catalytic subunit directly (Scott et al. 1985; Knighton et al. 1991; Kim et al. 2005) . When added, His-PKI completely eliminated the interaction between PKA-CS and PKA-RS ( Fig. 2A) . These experiments attest to the quality and functionality of the recombinant proteins used in our experiments.
The basal I Ba may be composed of current from non-phosphorylated and endogenously phosphorylated channels. To measure the contribution of phosphorylated Ca V 1.2 1821 to basal I Ba , we injected 156 μM His-PKI, 5-20 min before measuring I Ba . This caused a 40% reduction in I Ba compared to oocytes pre-injected with buffer alone (Fig. 2B) . Thus, about 40% of the amplitude may be due to endogenous PKA activity. To calculate the full span of the enhancing effect of PKA on Ca V 1.2 in our experiments, we took into account the PKA-dependent part of the basal current. A 40% increase in current due to cAMP or PKA-CS, on top of only 60% of the basal current, would yield a 1.4/0.6 = 2.3-fold increase of rabbit α 1C 1821 current due to PKA-CS activity.
To further examine the specificity of the cAMP and PKA-CS effects, we used the PKI protein (a direct inhibitor of PKA-CS) and an indirect PKA inhibitor, the cAMP diastereoisomer Rp-cAMPS, which competes with cAMP on the PKA-RS binding sites and inhibits the dissociation of PKA-CS from PKA-RS (Anand et al. 2010) . First, we validated the experimental protocol with CFTR as a PKA activation reporter. We pre-injected the inhibitors, and 5-30 min later measured the cAMP-induced CFTR Cl − currents. Rp-cAMPS was injected to obtain a final concentration of 2 mM, which is comparable to 1-5 mM used by others to inhibit the β-adrenergic regulation of Ca V 1.2 in whole-cell experiments in cardiomyocytes Hirayama & Hartzell, 1997) . Figure 3A shows that Rp-cAMPS inhibited the cAMP effect on CFTR by 89%, while pre-injection of H 2 O did not significantly alter the cAMP effect. Pre-injection of purified His-PKI to 2.5 μM (final concentration in the oocyte) yielded an 84% inhibition of cAMP-induced CFTR current, and a complete inhibition was achieved at 25 μM His-PKI (Fig. 3B ). This concentration range is similar to that employed by others who used PKI or PKI peptides to inhibit β-adrenergic regulation of Ca V 1.2 in cardiomyocytes (Kameyama et al. 1986; Parsons et al. 1991; Hartzell et al. 1995; Skeberdis et al. 1997) .
Next, we examined the effects of PKA inhibitors on cAMP regulation of Ca V 1.2 1821 using the same experimental protocol as for CFTR. Rp-cAMPS inhibited 80% of the cAMP-induced effect. Pre-injection of water did not alter the cAMP effect (Fig. 3C) . Similarly, the cAMP-induced increase in I Ba of Ca V 1.2 1821 was reduced by 89% when oocytes were pre-injected with His-PKI to a final concentration of 25 μM (Fig. 3D) . Taken together, the results so far suggest that cAMP-induced upregulation of both CFTR and Ca V 1.2 1821 channel currents in oocytes is a PKA-specific modulation that requires dissociation of PKA-CS from PKA-RS. The results of Fig. 1 demonstrate that truncation of the dCT of α 1C is essential for the PKA effect on Ca V 1.2. However, the presence of the 'clipped' dCT seems non-obligatory. To better understand the role of dCT in cAMP modulation of the truncated Ca V 1.2 1821 in Xenopus oocytes, we coexpressed Ca V 1.2 1821 with the dCT as a separate protein. We first examined whether the coexpression of dCT produces the two characteristic effects on the truncated Ca V 1.2: a reduction in maximal inward I Ba amplitude and a depolarizing shift of the activation (conductance-voltage, G-V) curve (Hulme et al. 2006; Fuller et al. 2010; Crump et al. 2013) .
Coexpression of dCT, at variable ratios of RNA concentrations of dCT and Ca V 1.2 1821 ('dCT:channel RNA ratio'), caused a large reduction of 60-70% in I Ba amplitude when using 2.5:1 to 5:1 dCT:channel RNA ratios (Fig. 4Aa) . The expression of dCT in the same batch of oocytes did not alter the channel density in the plasma membrane, as demonstrated using immunocytochemistry in giant excised plasma membrane patches (Fig. 4Ab and c) . Thus, the reduction in I Ba following coexpression of dCT resulted from a modification of the gating properties, and was not due to a change in channel expression. dCT titration using a wider range of RNA doses, while keeping the level of Ca V 1.2 1821 constant, revealed that current inhibition by dCT was dose dependent, reaching a maximal 50-60% reduction at 2.5:1 dCT:channel RNA ratio ( Fig. 4B and C) .
The coexpressed dCT also produced the second expected effect, the depolarizing shift of the G-V curve, increasing the half-maximal activation voltage (V a ). However, this effect took place only at dCT:channel RNA ratios of ࣙ10:1 (Fig. 4D and E, Table 2 ), much higher than required for the maximal effect of dCT on I Ba amplitude. Evidently, the expression of the dCT protein further increased at RNA ratios higher than 5:1, as it produced an effect not seen at lower RNA doses. Thus, the saturation of dCT action on I Ba amplitude at a 2.5:1 dCT:channel ratio reflects a genuine maximal reduction in I Ba rather than a limitation of the oocyte's expression machinery . A similar distinction between the actions of dCT on I Ba amplitude and G-V curve was previously reported in mammalian tsA-201 cells (Hulme et al. 2006; Fuller et al. 2010) ; it may imply distinct molecular mechanisms for the two effects. Statistical significance of the shift in half-maximal voltage (V a ) was determined using a t test, comparing to control group (no dCT expression). * * * P < 0.001; ns, not significant.
It has been proposed that the cleaved dCT interacts with the proximal part of the CT in Ca V 1.2 1821, and this interaction is essential for the proper regulation by PKA. By binding both α 1C (at the dCT) and PKA-RS, A-kinase-anchoring proteins (AKAPs) anchor PKA to Ca V 1.2. AKAP15 is an integral part of the Ca V 1.2 regulatory complex in cardiomyocytes (Catterall, 2015) , and it was also found indispensable for PKA modulation of Ca V 1.2 reconstituted in HEK cells (Fuller et al. 2010 (Fuller et al. , 2014 . In contrast, our data suggest that in Xenopus oocytes, neither dCT nor AKAP15 are essential for the cAMP effect on I Ba . We tested a range of dCT:channel and AKAP15:channel RNA ratios, but none have yielded a significant increase in cAMP effect on I Ba amplitude, compared with the channel alone (Fig. 5A) .
We used the AKAP blocker Ht31 (Tröger et al. 2012; Dema et al. 2015) to test the possibility that endogenous AKAPs in the oocytes optimize the channel complex, obviating the need for exogenously expressed AKAP15. However, EGFP-fused Ht31 peptide (Lynch et al. 2005) , which was well expressed in the oocytes as verified by confocal imaging, did not affect the cAMP-induced modulation of Ca V 1.2 1821 (Fig. 5B) . We conclude that, in Xenopus oocytes, reconstitution of PKA-CS regulation of Ca V 1.2 1821 does not necessitate the presence of dCT or AKAP.
J Physiol 595.10 cAMP modulation of Ca V 1.2 in Xenopus oocytes does not require the α 1C phosphorylation sites S1700 and T1704, or the Ca V β subunit Serine-1700 and threonine-1704 were proposed to be crucial for PKA-induced Ca V 1.2 upregulation reconstituted in HEK cells (Fuller et al. 2010) . We mutated these amino acids, separately or together, to alanines. These mutations did not attenuate the cAMP-dependent increase in Ca V 1.2 1821 currents in oocytes (Fig. 6A) .
The cardiac Ca V β subunit is phosphorylated in vivo following β-adrenergic stimulation (Haase et al. 1996) . However, the role of phosphorylation of Ca V β in PKA enhancement of Ca V 1.2 is controversial (compare Bunemann et al. 1999 vs. Miriyala et al. 2008 Brandmayr et al. 2012; Minobe et al. 2014, and see Discussion) . To test the involvement of Ca V β in our system, we prepared a construct, termed β 2b -4A, with four alanine mutations in PKA phosphorylation sites: serine 296 (Pankonien et al. 2012) , serines 479 and 480 (Bunemann et al. 1999 ) and serine 576 (Viard et al. 2004) . To exclude the involvement of any unrecognized phosphorylation sites in the CT of Ca V β, another construct, truncated after amino acid 470, was prepared (β 2b -CT trunc , Fig. 6Ba ). The two constructs, β 2b -4A and β 2b -CT trunc , were expressed in the oocyte along with the α 1C 1821 and α 2 δ subunits. The mutated Ca V β constructs did not attenuate the upregulation of I Ba following cAMP injection ( Fig. 6Bb and c) . Coexpression of AKAP15 and dCT constructs together with α 1C 1821 and α 2 δ and either β 2b -4A or β 2b -CT trunc did not significantly alter the cAMP effect on I Ba (Fig. 6Bb) . Furthermore, α 1C 1821 coexpressed with the α 2 δ subunit only, without Ca V β, showed cAMP modulation comparable to full subunit composition ( Fig. 6Bb and c) , indicating the redundancy of Ca V β in the cAMP modulation observed in Xenopus oocytes.
N-terminus of α 1C is involved in cAMP-dependent PKA upregulation of I Ba
The N-terminus (NT) of the cardiac α 1C encompasses an inhibitory module that regulates the channel's gating and is involved in Ca V 1.2 regulation by protein kinase C (PKC) (Shistik et al. 1998; Blumenstein et al. 2002; Weiss et al. 2012) . We hypothesized that the NT may also be involved in PKA-dependent regulation of Ca V 1.2.
The cytosolic NT domain of the cardiac 'long-NT' (LNT) α 1C isoform is 154 amino acids long. The first 46 amino acids are encoded by the variable exon 1a and the rest by the constant exon 2 (Blumenstein et al. 2002; Dai et al. 2002; Pang et al. 2003) . The inhibitory module comprises the first 20 a.a. of the initial 46 a.a. segment (Kanevsky & Dascal, 2006) . In the smooth muscle 'short-NT' (SNT) isoform, also abundant in the brain (Biel et al. 1990; Koch et al. 1990; Snutch et al. 1991) , the initial NT segment is 16 a.a. long and is encoded by exon 1 instead of 1a (Abernethy & Soldatov, 2002) . The SNT α 1C does not contain an inhibitory module, and is not upregulated by PKC in Xenopus oocytes (Kanevsky & Dascal, 2006) .
We compared the cAMP regulation of LNT and SNT α 1C isoforms, as well as a series of additional NT deletions and chimeric constructs, created on the template of the CT-truncated α 1C 1821 (numbering by LNT isoform) (Fig. 7A) . cAMP injection into oocytes expressing the SNT α 1C 1821 isoform failed to enhance I Ba , in contrast with the cardiac LNT α 1C 1821. The removal of most of the NT (LNT 139) or of the inhibitory gating element alone (the first 20 a.a. of the LNT; LNT 20) abolished the cAMP-dependent increase in I Ba (Fig. 7A and B) . These results show that the initial 20 a.a. are essential for PKA regulation.
Importantly, addition of the inhibitory module (the first 20 a.a.) directly to the rest of NT encoded by exon 2 (by removing the last 26 amino acids of the exon 1a-encoded Deletion of amino acids 2-5 in the inhibitory gating element of the LNT α 1C 1821 eliminated the cAMP regulation (the LNT 5 construct), and greatly reduced it by ß70% when both amino acids 2-5 and amino acids 20-46 of LNT α 1C 1821 were deleted ). Yet, adding amino acids 2-5 or amino acids 20-46 of the long NT to the SNT α 1C 1821 did not render the SNT channel cAMP sensitive (chimeras 'SNT+a.a.2-5' and 'SNT+a.a.20-46'). Thus, amino acids 2-5 are essential but not sufficient for cAMP-dependent current upregulation.
The initial five amino acids of the LNT isoform are not fully conserved in different species. The a.a. sequence is MLRAL in rabbit, MLRAF in human, and MIRAF in mouse LNT α 1C . We have tested for Figure 6 . cAMP-dependent I Ba upregulation is not affected by alanine mutations of S1700 and T1704 in α 1C , or by the Ca V β subunit A, mutation S1700A, T1704A, or both to alanine do not alter the extent of cAMP upregulation of Ca V 1821. a, summary of cAMP effect. N = 2 experiments. No statistical significance was found using one-way ANOVA test. b, representative time course charts of changes in I Ba following cAMP injection (200 μM). Insets in b show I Ba current traces in the same cell. B, the presence of Ca V β 2b subunit, or mutations in Ca V β 2b phosphorylation sites, do not alter cAMP regulation. a, an illustration of the constructs used. SH3 and GK are structural modules within the β subunit. Numbers indicate amino acids. b, summary of % increase in I Ba per cell, following cAMP injection. Oocytes were injected with the following RNAs: 1 ng α 1C 1821, α 2 δ1 and either Ca V β 2b -wild-type (WT), Ca V β 2b -4A or Ca V β 2b -CT trunc , with or without 2.5 ng AKAP15 and 5 ng dCT. α 1C 1821 RNA (7 ng) was injected when Ca V β 2b subunit was not present (α 1C 1821 and α 2 δ1 only). No statistical significance was found using one-way ANOVA test. c, representative time course charts of I Ba following cAMP injection (200 μM). Insets show current traces in the same cells.
J Physiol 595.10 potential species variability in PKA regulation using mouse α 1C . Figure 8A -C shows that the dCT-truncated mouse α 1C 1821 was strongly regulated by the injection of purified PKA-CS, with an average increase of 126 ± 23% (n = 12), which is almost 3-fold greater than the average ß40% increase observed in rabbit Ca V 1.2 1821 (compare to Fig. 1G) . Deletion of amino acids 2-5 (Ca V 1.2 5 1821) strongly reduced, but did not eliminate, the PKA-CS effect: a residual 29 ± 12% increase was still present (Fig. 8B and C) . Full-length α 1C with the deletion of amino acids 2-5 (Ca V 1.2 5-full) was not upregulated by PKA-CS. 
LNTΔ20-46
SNT+a.a.20-46 MVNENTR MYIPEENHQL SAETESTCKG TVVHEAQLNH FYISPGGSNY...
.. . In summary, the experiments with the N-terminal mutants of rabbit and mouse α 1C suggest that the initial 20 amino acid segment of α 1C uniquely present in the cardiac LNT isoform is essential for the cAMP and PKA regulation of Ca V 1.2 1821 in Xenopus oocytes. This segment is also sufficient to render the channel sensitive to PKA when the rest of the channel (starting from the exon 2-encoded part) is present. The few partly conserved amino acids at the very beginning of this segment play an important role, and their removal eliminates >70% of the PKA effect.
Discussion
The intensive effort to understand the mechanism of PKA regulation of Ca V 1.2 has not yet yielded a unifying mechanistic insight. Studies in genetically modified cardiomyocytes and mice refuted the proposed crucial roles of putative target phosphorylation sites in α 1C and β subunits suggested by in vitro and heterologous studies. Disappointingly, so far, studies with genetically engineered animals also did not positively resolve the puzzle (Weiss et al. 2013; Hofmann et al. 2014; Catterall, 2015; Morrow & Marx, 2015) . Nevertheless, one major mechanistic insight is shared by most published works: the involvement of the distal C-terminus (dCT) of α 1C , and the importance of its naturally occurring post-translational truncation (Fuller et al. 2010; Domes et al. 2011; Fu et al. 2011) . With this in mind, in this work we have re-examined the possibility of utilizing the Xenopus oocyte to search for additional unknown components of the PKA regulatory mechanism.
We succeeded to reconstitute the cAMP/PKA regulation of the dCT-truncated Ca V 1.2 in Xenopus oocytes, a task which previously failed with the full-length, non-truncated α 1C . A reproducible whole-cell current increase of Ca V 1.2 from two species, rabbit and mouse, has been observed in single oocytes following intracellular application (injection) of cAMP or PKA-CS. Although truncation of the dCT was essential, the presence of the clipped dCT or AKAP15 was not. The cAMP/PKA effect did not involve the phosphorylation sites S1700 and T1704 in α 1C , or the β subunit of the channel, in line with recent animal model studies (Brandmayr et al. 2012; Yang et al. 2013) . These findings pave the way for the further use of this versatile and easily manipulated heterologous system to pinpoint the molecular determinants of PKA modulation within Ca V 1.2. To this end, using a standard mutagenesis approach, we identified the initial segment of the cardiac LNT isoform of α 1C as a previously unrecognized requisite structural element involved in PKA regulation. This finding raises the possibility that PKA is acting, in part, by affecting the hypothesized synergistic regulation of Ca V 1.2 by a scaffold formed by cytosolic Nand C-termini of α 1C (Ivanina et al. 2000; Dick et al. 2008; Benmocha Guggenheimer et al. 2016) . We further propose that the new mechanism may be one of two or more complementary pathways of PKA regulation of Ca V 1.2 in the heart. channels. First, we used two-electrode voltage clamp with sharp electrodes and injected cAMP, PKA-CS and other substances directly into the cell. This method avoids the dilution of the cytosol and the accompanying rundown of the channel's current inherent in whole-cell patch clamp (Weiss et al. 2013 ) used in mammalian cell models. Further, the injection technique allowed Ba 2+ currents to be measured via Ca V 1.2 before and after cAMP/PKA addition in the same cell, thus allowing sensitive detection of even small changes in whole-cell currents. Finally, oocytes are highly suitable for titrated expression of proteins, due to precise control of the amount of injected RNA (e.g. Yakubovich et al. 2015) .
As positive control for the functional effects of cAMP and PKA-CS in Xenopus oocytes, we monitored PKA-dependent changes in Cl − currents of the CFTR channel, a well-characterized PKA effector (Gadsby & Nairn, 1999 ). CFTR's Cl − currents were greatly enhanced by the injection of cAMP or PKA-CS, and specificity of PKA regulation was confirmed through inhibition by the inactive cAMP analogue Rp-cAMPS and the highly specific PKA inhibitory protein PKI (Fig. 3) . By using the same concentrations of Rp-cAMPS and PKI, we confirmed the inhibition of cAMP-dependent Ca V 1.2 1821 upregulation ( Fig. 3C and D) . Thus, the regulation of Ca V 1.2 is PKA specific.
The results also strongly suggest that the observed cAMP regulation involved the classical mechanism of dissociation of PKA-CS from the PKA-RS which, in the absence of cAMP, is strongly associated with, and inhibits the activity of, PKA-CS (Taylor et al. 2012) . This is supported by the enhancing action of purified PKA-CS and the strong blocking effect of Rp-cAMPS, which acts mainly by preventing the dissociation of the PKA holoenzyme (Anand et al. 2010 ).
The discrepancies with previous reports
The open questions regarding the mechanism of PKA regulation of Ca V 1.2 have been thoroughly reviewed in the past (Weiss et al. 2013; Hofmann et al. 2014 ). There were disagreements on experimental findings even in the same expression system such as HEK cells or their derivative, the tsA cell line (for example, Gao et al. 1997 J Physiol 595.10 vs. Fuller et al. 2010 vs. Zong et al. 1995 . At the same time, there was a general consensus on the absence of PKA upregulation of full-length (untruncated) Ca V 1.2 across different heterologous systems Singer-Lahat et al. 1994; Zong et al. 1995) , as confirmed here (Fig. 1) . In the following we discuss how some of the discrepancies can be reconciled considering potential differences between cell types and the importance of colocalization of Ca V 1.2 and PKA in cardiomyocytes. Our emphasis is on the recent extensive studies of Fuller et al. done in tsA cells (Fuller et al. 2010 (Fuller et al. , 2014 . The two major points of disagreement with the latter work are the requirement for a simultaneous presence of dCT and AKAP, and the importance of phosphorylation of S1700 and T1704.
Truncation of dCT is crucial for PKA regulation of Ca V 1.2, but the dCT and AKAP15 are not essential
Our study agrees with that of Fuller et al. (2010) in one central aspect: as in tsA cells, in the oocytes the truncation of dCT of α 1C is essential for PKA-induced regulation of Ca V 1.2. In the oocytes, current via the dCT-truncated channel, Ca V 1.2 1821, was increased by ß40% (rabbit) or ß130% (mouse α 1C ) by the injected cAMP or purified PKA-CS, whereas the full-length channel was not regulated (Figs 1 and 8) .
In our hands, the PKA-induced increase in current amplitude of Ca V 1.2 1821 in the oocytes did not require the clipped dCT, and cAMP-induced increase in channel current was not altered in the very wide dCT titration range used here. The dCT was synthesized and expressed as a separate protein in the oocytes, and interacted with α 1C , because it produced the two well-documented effects on the truncated Ca V 1.2: a reduction in whole-cell current (without any change in surface expression of α 1C ) and, at higher expression levels of the dCT, a depolarized shift in channel activation (Fig. 4) (Hulme et al. 2006; Fuller et al. 2010) .
Further, titration of AKAP15 had no additional effects on cAMP-dependent upregulation of Ca V 1.2 1821 (Fig. 5) . We cannot completely rule out a role for an endogenous oocyte AKAP. However, two lines of evidence argue against this possibility. First, Ht31, a peptide that inhibits interaction of AKAPs with the PKA regulatory subunit and disrupts PKA anchoring by AKAPs, did not influence the effect of cAMP. Second, the dCT, which anchors both AKAP15 and AKAP79 to α 1C (Catterall, 2015) , was not needed. The expendability of AKAP does not contradict in vivo studies, because PKA regulation of cardiac Ca V 1.2 is preserved after knockout of AKAP15 and AKAP79/150 in mice (Nichols et al. 2010; Jones et al. 2012) .
The above results are at odds with the reported necessity for the simultaneous presence of dCT and AKAP in the tsA-201 cell line, where cAMP levels were elevated with the adenylyl cyclase activator, forskolin (Fuller et al. 2010 (Fuller et al. , 2014 . Nevertheless, a comparative analysis of oocyte and tsA-201 data offers a plausible way to reconcile among them, and to explain why forskolin cannot regulate Ca V 1.2 1821 in the absence of dCT and AKAP in tsA-201 cells. The logic is as follows:
(1) It is widely agreed that AKAP is needed only for anchoring the PKA close to the channel; it is not implicated in the end-point of regulation itself (Catterall, 2015 Fuller et al. (2010) data show the necessity of the dCT for anchoring of PKA to α 1C via AKAP, but do not necessarily implicate the dCT in the end-point regulation mechanism itself. (5) In the oocytes, we are providing the injected cell with ample cAMP or purified PKA-CS, which obviously bypasses the need for PKA anchoring near the channel, since we see a bold regulation without adding AKAPs.
In partial support of this hypothesis, a previous study in HEK cells reported upregulation of Ca V 1.2 by infused PKA-CS in the absence of dCT or AKAP, when α 1C was truncated at amino acid 1905 (Bunemann et al. 1999) .
We conclude that, on the factual level, the dispensability of dCT and AKAP15 in oocytes does not necessarily contradict the phenomena observed in HEK/tsA cells. However, on the mechanistic level, our findings do not support the elegant mechanism proposed by Catterall and colleagues (Fuller et al. 2010) , where phosphorylation of S1700 removes a dCT-imposed channel inhibition. This is because in the oocytes PKA regulates Ca V 1.2 1821 in the absence of dCT. Notably, Beam et al. arrived at a similar conclusion for the skeletal muscle Ca V 1.1, where dCT is truncated but does not associate with or modulate the channel, yet the channel is regulated by PKA, though rather modestly (Ohrtman et al. 2015) . The expendability of dCT does not undermine the importance of the rest of the CT for PKA regulation. For instance, the fact that in the context of full-length α 1C the dCT impairs the effect of PKA hints upon a folding effect of the dCT, possibly by its binding to proximal CT. On the basis of experiments in HEK cells, phosphorylation of C-terminal serines in the Ca V β subunit has been proposed to play a major role in PKA regulation of Ca V 1.2 (Bunemann et al. 1999) . In our oocyte system, cAMP similarly regulated Ca V 1.2 1821 with or without the coexpression of the Ca V β subunit (Fig. 6) . Involvement of the oocytes' endogenous Ca V β 3 subunit (Tareilus et al. 1997 ) is unlikely, since Ca V β subunit overexpression greatly changes the amplitude and activation of the expressed Ca 2+ channels, suggesting that most of them are not pre-associated with the endogenous Ca V β (Canti et al. 2001) . By mutagenesis, we rule out the involvement of Ca V β phosphorylation sites 296, 479, 480 and 576. Our results corroborate the previous expression studies in the mammalian BHK cell line (Minobe et al. 2014 ) and in cardiomyocytes (Miriyala et al. 2008) , and in genetically engineered mice, where truncation of Ca V β at position 450 (a.a. count according to rabbit Ca V β 2b isoform used here) did not affect β-adrenergic I Ca upregulation (Brandmayr et al. 2012) . Taken together, our data suggest that phosphorylation of the Ca V β subunit is not involved in the PKA effect on Ca V 1.2 1821 reconstituted in Xenopus oocytes.
The role of PKA phosphorylation sites in the α 1C subunit has been highly controversial. The involvement of S1928, a major PKA phosphorylation site previously thought to mediate the PKA effect (reviewed in Weiss et al. 2013) , was ruled out by functional studies in genetically engineered cardiomyocytes and mice (Ganesan et al. 2006; Lemke et al. 2008) . Phosphorylation of this serine has recently been found crucial for uncoupling of the direct interaction between β2AR and Ca V 1.2 (Patriarchi et al. 2016 ). In our system, S1928 is irrelevant because it is located in the dCT which is not needed for the PKA regulation of Ca V 1.2 1821.
Phosphorylation of two additional sites located in the proximal CT, S1700 and T1704 (Norman & Leach, 1994; Fuller et al. 2010) , has been proposed to mediate the effect of PKA in Ca V 1.2 by weakening the interaction of dCT with a proximal CT-acceptor site, PCRD (Fuller et al. 2010; Catterall, 2015) . However, more recently it has been proposed that T1704 (which is not a PKA but rather a casein kinase site; Fuller et al. 2010 ) is probably not involved in PKA regulation but may contribute to the basal activity of the channel (Fu et al. 2014 ). In our case, alanine mutations of S1700 and T1704 in Ca V 1.2 1821 expressed in oocytes did not reduce the sensitivity to cAMP (Fig. 6A) . This result correlates with the reported lack of effect of mutating these residues in a mouse model with inducible expression of the mutated α 1C (Yang et al. 2013) . Nevertheless, studies of a different mouse model show that mutation of S1700 alters the regulation of Ca V 1.2 function, and PKA and Ca 2+ handling in mouse heart (Fu et al. 2014; Yang et al. 2016) , although the exact role of phosphorylation of S1700 in overall PKA effect on Ca V 1.2 itself may need further clarification. In heterologous systems, diverse cellular properties certainly may play a role, such that the fractional contribution of phosphorylation of S1700 (possibly followed by separation of the dCT) is prominent in tsA cells but not in the oocytes. Resolving this conundrum will require further study.
A novel mechanism involving the N-terminus of α 1C
We have utilized the newly developed experimental approach to look for additional molecular determinants of PKA regulation in α 1C . The NT is an important regulatory domain that controls the channel's open probability, trafficking and inactivation (Shistik et al. 1998; Ivanina et al. 2000; Kanevsky & Dascal, 2006; Dick et al. 2008; Thomsen et al. 2009; Simms et al. 2015) . Previously we have shown that PKC regulation of Ca V 1.2 expressed in Xenopus oocytes is controlled by the NT inhibitory gating element through a mechanism that does not involve phosphorylation of the gating element itself, and does not require the C-terminal truncation of α 1C (Shistik et al. 1998 (Shistik et al. , 1999 Blumenstein et al. 2002) . This gating element comprises the first 20 amino acids, out of the 46 amino acids encoded by exon 1a, of the 'cardiac' LNT isoform of α 1C (Kanevsky & Dascal, 2006 ). Here we show that this 20 a.a. segment is essential for PKA regulation of cardiac Ca V 1.2 reconstituted in Xenopus oocytes (Fig. 7) . This 20 a.a. segment is also sufficient for rendering the Ca V 1.2 1821 sensitive to PKA when added to the rest of α 1C starting from the part of NT encoded by the obligatory exon 2. The partially homologous 16 a.a. segment of the short NT isoform, encoded by exon 1, does not carry this property, implying the presence and importance of a highly specific element or structure within the 20 amino acids of the cardiac LNT isoform of α 1C . The first five amino acids may be part of this element, since the removal of this segment reduced the PKA effect by >70% (Figs 7 and 8) . Nevertheless, the addition of five initial amino acids did not confer PKA regulation upon the SNT Ca V 1.2 1831. Thus, the first five amino acids are important, but not sufficient for the PKA effect. We have previously proposed that NT and CT may act together as one functional unit (an 'NT-CT scaffold') to regulate the channel's gating (Ivanina et al. 2000) , and demonstrated a direct interaction (binding) between the NT and CT of α 1C (Benmocha Guggenheimer et al. 2016) . We hypothesize that the 'NT-CT scaffold' participates in PKA regulation of Ca V 1.2 gating.
One or more mechanisms of Ca V 1.2 regulation by PKA?
The regulation of α 1C truncated at 1821 is at odds with two reports in genetically engineered cardiomyocytes and J Physiol 595.10 mice, where truncation of α 1C at a.a. 1905 or 1796 produced channels with low or no sensitivity to β-AR and PKA activators (Ganesan et al. 2006; Fu et al. 2011) . Notably, however, in genetically engineered mice the expression of C-terminally truncated channels is severely reduced, and localized expression of AKAP15 is also reduced (Domes et al. 2011; Fu et al. 2011) . In cardiomyocytes, the truncated channels were expressed ectopically (Ganesan et al. 2006 ) and might have not been localized in the correct cellular compartment. The β2AR is also expected to uncouple from Ca V 1.2 in the absence of dCT of α 1C (Patriarchi et al. 2016) . Localization is crucial in cardiomyocytes (Balijepalli et al. 2006; McConnachie et al. 2006) . Therefore, one reason for the observed lack of regulation could be insufficient anchoring of components of the β-AR-PKA pathway in the vicinity of the channel, or insufficient increase in cAMP concentration at the channel's location. Under our conditions, we saturated the channel with an excess of injected cAMP or PKA-CS to achieve the maximal possible response. Another (or an additional) possibility is that the mechanism described here is one of two or several redundant PKA regulation pathways (Weiss et al. 2013 ) that, together, produce the strong regulation of the channel observed in cardiomyocytes.
In this respect, it is interesting to compare the extent of increase in Ca 2+ channel currents in cardiac cells of the relevant species with that seen in our system. In isolated rabbit cardiomyocytes, the increase in the current above basal level varies from 50 to 130% with isoproterenol (isoprenaline) or forskolin (Han et al. 1994; Shannon et al. 1995; Matsuda et al. 1996; Ginsburg & Bers, 2004) . In the mouse, the current is increased by β-AR activation anywhere from 45 to 200% above the basal level Heubach et al. 1999; Lemke et al. 2008) , 50-100% by forskolin, and up to 200% above baseline by purified PKA-CS (Maltsev et al. 1999) . The 40% increase caused by cAMP of PKA-CS with rabbit Ca V 1.2 1821 and the ß130% increase caused by PKA-CS with mouse Ca V 1.2 1821 are comparable to the lower or medium values from this (admittedly incomplete) list. It is therefore plausible that the observed effect might account for only a part of the total PKA regulation. As discussed above, phosphorylation of S1700 may be the other molecular event contributing to the total regulation.
In summary, we propose that several PKA regulation pathways may exist under physiological conditions. The regulation of the truncated Ca V 1.2 observed in the Xenopus oocyte expression system appears to be a very basic one, inherent to α 1C . It does not require the β subunit, AKAPs or the dCT (the latter actually hinders the regulation in the context of a full-length, non-truncated α 1C ). This expression system proved appropriate to observe the specific PKA regulation of the C-terminally truncated channel and to uncover the potential role of the NT. In native heart cells, more layers of complexity are added by localization and compartmentalization, anchoring, and regulatory proteins and other factors. The basic regulation of the truncated α 1C may coexist with AKAP15 and dCTdependent regulation (Catterall, 2015) , or some as yet unknown regulation of the full-length (non-truncated) α 1C , which may differentially contribute to the total PKA effect.
